Related Experiment Videos

Myocardial injury produced by antineoplastic drugs

Recent Advances in Studies on Cardiac Structure and Metabolism
|January 1, 1975
PubMed

Insights

High-dose anthracyclines and cyclophosphamide can cause significant heart damage in cancer patients. These chemotherapy drugs led to myocardial degenerative lesions and necrosis in a recent histologic study.

Area of Science:

  • Cardiology
  • Oncology
  • Pathology

Background:

  • Cancer therapies, including anthracyclines and cyclophosphamide, are associated with potential cardiotoxicity.
  • Understanding the specific cardiac manifestations of these treatments is crucial for patient management.

Purpose of the Study:

  • To investigate the histologic and ultrastructural cardiac effects of high-dose anthracyclines and cyclophosphamide in patients with fatal leukemias or solid tumors.

Main Methods:

  • Histologic and ultrastructural examination of myocardial tissue from 16 patients with fatal malignancies.
  • Correlation of cardiac findings with chemotherapy treatment regimens, specifically anthracycline and cyclophosphamide doses.

Main Results:

  • Multifocal myocardial degenerative lesions were observed in 12 of 13 patients treated with high-dose anthracyclines.
  • One patient receiving high-dose cyclophosphamide and daunorubicin showed extensive hemorrhagic myocardial necrosis.
  • Cardiac damage was absent in a control group of 3 patients not receiving high-dose therapy.

Conclusions:

  • High total doses of anthracyclines are associated with significant cardiotoxic effects, manifesting as myocardial degenerative lesions.
  • Concomitant high-dose cyclophosphamide and anthracyclines can lead to severe cardiac pathology, including necrosis.
  • This study highlights the detrimental impact of specific chemotherapy agents on cardiac tissue.

Related Concept Videos